

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S.Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/659,747 INFORMATION DISCLOSURE Filing Date September 11, 2003 STATEMENT BY APPLICANT Alexander LEVITZKI et al First Named Inventor Art Unit (use as many sheets as necessary) JONES, DAMERON LEVEST Examiner Name Attorney Docket Number 26682 2 Sheet U.S. PATENT DOCUMENTS Pages, Columns, Lines, Where Examiner Cite Document Number Publication Date Name of Patentee or Relevant Passages or Relevant Applicant of Cited Document MM-DD-YYYY Figures Appear Number-Kind Code² (if known) Wissner et al. US-6,251,912 06-26-2001 1 Wissner et al. 2 US-5,760,041 02-2-1998 11-28-2000 **Bridges** US-6,153,617 3 03-3-2000 **Bridges** US-6,127,374 4 09-12-2002 Mishani et al. US-2002/0128553

		FOREIGN	PATENT DOC	UMENTS		
Examiner Initials*	Cite No. ¹	Foreign Patent Documents Country Code ^b Number ^b Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7 6
10	6	PCT WO 02/073235	09-19-2002	Levitzki et al.		L
1.7	7	PCT WO 2005/023315	03-17-2005	Mishani et al.		L
11/	8	PCT WO 99/09016	02-25-1999	Wissner et al.		丄
9		PCT WO 2004/046101	03-3-2004	Wallace et al.		L
\exists						╀-
			<u> </u>	<u></u>		
Examiner Signature		0		Date Considered	2/16/06	7

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Set Kinds

Set Kinds

Fig. 1. Applicant surrique creation designation number (optional). Set Kinds

of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or MPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or MPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or MPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or MPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or MPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or MPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or MPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or MPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or MPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or MPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or WPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or WPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or WPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or WPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or WPEP 901.04. Set Kinds

The Comment of Comments at www.uspto.gov or white Set Kinds

The Comment of Comments at www.uspto.gov or white Se ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

PTO/SB/08b (08-03)

Approved for use through 06/30/2006. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE uired to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwe	ork Reduction	Act of 1995, to Page 314 required to respond to a coll	ection of unformation un	Complete	f Known				
	Sub	stitute for form 1449A/PTO	Application Number						
	INFO	ORMATION DISCLOSURE	Filing Date	September 11, 2003					
		TEMENT BY APPLICANT	First Named Inventor	Alexander LEVITZKI et al					
		(use as many sheets as necessary)	Group Art Unit	1618					
	,	use as many sneets as necessary)	Examiner Name	JONES, DAMERON LEVEST					
Sheet	2	Of	2	Attorney Docket Number	26682				
		OTHER PRIOR ART – NON I	PATENT LITER	ATURE DOCUMENTS					
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LE item (book, magazine, journal, serial sympos publisher, city an	ium, catalog, etc.) da d/or country where p	te, page(s), volume-issue numb ublished.	er(s),	T ²			
TY	Smaill et al. "Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)Quinazoline- and 4- (Phenylamino)Pyrido[3,2-d]Pyrimidine-6-Acrylamides Bearing Additional Solubilizing Functions", Journal of Medicinal Chemistry, 43: 1380-1397, 2000.								
	11	Compound 18, 25-27, Table 1. Smaill et al. "Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)Quiazoline and 4- (Phenylamino)Pyrido[d]Pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor", Journal of Medicinal Chemistry, 42: 1802-1815, 1999.							
	12	Mishani et al. "Carbon-11 Labeling o (Phenylamino)-Quinazolin-6-Yl]-Am Inhibitors", Journal of Labelled Comp 2003. Abstract.	ides, A New Clas	ss of EGFR Irreversible	: S2,				
	13	Ortu et al. "Labeled EGFR-TK Irreve Properties, Potential as Pet Biomarke Drug", International Journal of Cance Col.1, § 1, Fig.1.	r for Cancer and	Feasibility as Anticancer					
	14	Johnström et al. "Synthesis of [Methor Tyrosine Kinase Inhibitor", Journal o Radiopharmaceuticals, XLI: 623-629	f Labbelled Com , 1998. P.627, Fig	pounds and g.3.					
N	15	Mishani et al. "Novel Carbon-11 Lab (Phenylamino)-Quinazoline-6-Yl]-Ar Imaging of EGFR-Positive Tumors", 2004. P.474, Col.2, § 4 - P.475, Figs.	nides: Potential I Nuclear Medicin	PET Bioprobes for Molec	ular				
									

Signature

Considered

^{*}EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with hext communication to applicant.

1. Applicant's unique citation designation number (optional). 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.14. this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.